LAVAL, QC / ACCESS Newswire / September 5, 2025 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in the medical aesthetics market, today announced that the Company's proven Thermage technology has successfully been used to perform more than 5 million skin tightening and smoothing treatments. Thermage utilizes monopolar radiofrequency energy... Read More

LAVAL, QC AND CUPERTINO, CA / ACCESS Newswire / August 26, 2025 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC), a global, diversified pharmaceutical company, and DURECT Corporation (NASDAQ:DRRX) today announced that BHC Lyon Merger Sub, Inc. ("Purchaser"), a wholly owned subsidiary of Bausch Health Americas, Inc. ("BHA"), and an indirect subsidiary of Bausch Health Companies Inc. ("BHC"), has extended the expiration... Read More

LAVAL, QC / ACCESS Newswire / August 21, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC), a global, diversified pharmaceutical company, today announced that Pr CABTREO ™ (clindamycin phosphate, adapalene and benzoyl peroxide) gel 1.2% w/w, 0.15% w/w and 3.1% w/w, for the treatment of acne vulgaris, 1 is now available to beneficiaries of the public drug plans of Quebec and... Read More

LAVAL, QC / ACCESS Newswire / August 15, 2025 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) ("Bausch Health" or the "Company") today announced that Paulson Capital Inc. and certain affiliates and managed funds have increased their ownership of the Company's common shares. The increase reflects the acquisition by Paulson Capital Inc. and certain affiliates and managed funds of the net long position of 34,721,118 common... Read More

For the Sixth Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 Scholarship LAVAL, QC / ACCESS Newswire / August 7, 2025 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the recipients of its 2025 Salix Gastrointestinal Health Scholars Program. For the sixth year, Bausch Health is proud to award... Read More

Second Quarter Consolidated Revenues of $2.53 billion, up 5% on a Reported basis and 4% on an Organic (non-GAAP) 1 basis over the prior year period GAAP Net Income Attributable to Bausch Health Companies of $148 million and GAAP Net Income of $128 million Consolidated Adjusted EBITDA Attributable to Bausch Health Companies (non-GAAP) 1 of $842 million, up 6% on a Reported basis over the prior year period BAUSCH HEALTH... Read More

DURECT's lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy Designation Potential to be the first FDA-approved therapeutic option for the treatment of patients with alcoholic hepatitis Proposed acquisition strengthens Bausch Health's commitment to hepatology and patients suffering with liver disease complications globally LAVAL, QC AND CUPERTINO, CA / ACCESS Newswire / July 29, 2025 / Bausch... Read More

LAVAL, QC / ACCESS Newswire / July 28, 2025 / Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) ("Bausch Health" or the "Company") today announced that its subsidiary, Bausch Health Americas, Inc., has issued an irrevocable notice of redemption pursuant to which it will redeem approximately $602 million of aggregate principal amount of its outstanding 9.25% Senior Notes due 2026, CUSIP Nos. 91911XAV6 and U9098VAN2 (the... Read More

LAVAL, QC / ACCESS Newswire / July 24, 2025 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC), a global, diversified pharmaceutical company, today announced the appointment of Michael Goettler and Sandra Leung to its Board of Directors, effective July 22, 2025. The appointments increase the size of the Board from ten to twelve members. Michael Goettler is an accomplished executive with extensive leadership experience in... Read More

This press release updates the headline of the previously posted release LAVAL, QC / ACCESS Newswire / July 10, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC), today announced that Pr CABTREO TM (clindamycin phosphate, adapalene and benzoyl peroxide) gel 1.2% w/w, 0.15% w/w and 3.1% w/w, for the treatment of acne vulgaris, 1 is now available to beneficiaries of the public drug... Read More

LAVAL, QC / ACCESS Newswire / July 10, 2025 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC), a global, diversified pharmaceutical company, today announced the appointment of Steven Lee as Senior Vice President, Controller and Chief Accounting Officer, effective Monday, July 14. Steven brings extensive experience in financial transformation, mergers and acquisitions, and operational execution. With over two decades of... Read More

LAVAL, QC / ACCESS Newswire / July 9, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that Pr CABTREO TM (clindamycin phosphate, adapalene and benzoyl peroxide) gel 1.2% w/w, 0.15% w/w and 3.1% w/w, for the treatment of acne vulgaris, 1 is now available to beneficiaries of the public drug plans of Ontario and Nova Scotia as well as through the federal government's... Read More

Focused on highlighting real patient experiences, Salix continues to lead the charge in educating and advocating for the hepatic encephalopathy community LAVAL, QC / ACCESS Newswire / July 7, 2025 / Bausch Health Companies Inc . (NYSE:BHC) (TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced its new direct-to-consumer (DTC) "I Wish I Knew" campaign for Xifaxan® (rifaximin), the... Read More

LAVAL, QC / ACCESS Newswire / July 2, 2025 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) will release second quarter 2025 financial results after market close on Wednesday, July 30, 2025. Bausch Health will host a conference call and live webcast at 5:00 p.m. U.S. EDT to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website... Read More

LAVAL, QC / ACCESS Newswire / May 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) today announced the election of the 10 directors nominated at its 2025 annual meeting of shareholders ("Annual Meeting") held on May 13, 2025. The detailed results of the vote for the election of directors are set out below: Name For Withheld Broker Non-Votes Thomas J. Appio 208,400,572 5,943,436 56,339,806 Christian A. Garcia... Read More

New analysis suggests efficacy of Xifaxan to mitigate OHE rehospitalizations irrespective of treatment history LAVAL, QC / ACCESS Newswire / May 6, 2025 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC), a global, diversified pharmaceutical company, and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced new data showing that people hospitalized due to overt hepatic encephalopathy (OHE) had... Read More

First Quarter Consolidated Revenues of $2.26 billion, up 5% on a Reported basis and 6% on an Organic (non-GAAP) 1 basis over the prior year period GAAP Net Loss Attributable to Bausch Health Companies of $58 million and GAAP Net Loss of $86 million Consolidated Adjusted EBITDA Attributable to Bausch Health Companies (non-GAAP) 1 of $661 million, in line with prior year period BAUSCH HEALTH EXCLUDING BAUSCH + LOMB FIRST... Read More

A Long-Awaited Advancement in Non-Invasive Radiofrequency Skin Tightening Is Now Approved for the Canadian Market LAVAL, QC / ACCESS Newswire / April 29, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its aesthetic business, Solta Medical, announced today that Health Canada has granted medical device license clearance for Thermage® FLX, the latest generation of the... Read More

The next generation of skin resurfacing technology will debut at the ASLMS 2025 Conference LAVAL, QC / ACCESS Newswire / April 25, 2025 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC), a global, diversified pharmaceutical company, and its aesthetics business, Solta Medical, announced today Fraxel FTX™ will launch at the American Society for Laser Medicine & Surgery, Inc. (ASLMS) 2025 Annual Conference on April 25 in... Read More

Supplement In Response to Company Learning that Carl Icahn and Affiliates Have Cash-Settled Equity Swaps for Approximately 90 Million of Its Common Shares LAVAL, QC / ACCESS Newswire / April 22, 2025 / Bausch Health Companies Inc. (NYSE:BHC) (TSX: BHC) (the "Company" or "Bausch Health") today announced that it has filed a supplement (the "Proxy Statement Supplement") to its proxy statement dated April 2, 2025 (the "Proxy... Read More

LAVAL, QC / ACCESS Newswire / April 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) (the "Company" or "Bausch Health"), and its gastroenterology business Salix Pharmaceuticals, Inc., today announced the U.S. District Court for the District of Columbia in the matter of Norwich Pharmaceuticals, Inc. v. Kennedy, et al. (Case No. 25-cv- 00091), denied Norwich's motion for a preliminary injunction treated as a motion... Read More

LAVAL, QC / ACCESS Newswire / April 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) (the "Company" or "Bausch Health") announces today that its board of directors (the "Board") has approved the adoption of a shareholder rights plan (the "SRP") pursuant to a shareholder rights plan agreement entered into with TSX Trust Company, as rights agent, dated April 14, 2025 (the "Effective Date"). The SRP has been adopted... Read More

Bausch Health is offering scholarships to six students impacted by dermatologic conditions, with application submissions open through June 11, 2025 LAVAL, QC / ACCESS Newswire / April 10, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC)and its dermatology business, Ortho Dermatologics, today announced the 2025 ASPIRE HIGHER Scholarship Program is now open for application submissions through June 11, 2025. The program... Read More

LAVAL, QC / ACCESS Newswire / April 9, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that it has signed a letter of intent with the pan-Canadian Pharmaceutical Alliance (pCPA) for Canadian public drug plan coverage for Pr CABTREO TM (clindamycin phosphate, adapalene and benzoyl peroxide) gel 1.2% w/w, 0.15% w/w and 3.1% w/w, a new triple-combination topical... Read More

Bausch Health's gastroenterology business, Salix Pharmaceuticals, recognizes the complexities of irritable bowel syndrome (IBS) and seeks to make a difference in how the condition is perceived, diagnosed and treated. LAVAL, QC / ACCESS Newswire / April 2, 2025 / Bausch Health Companies Inc . (NYSE:BHC) (TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the launch of IBS... Read More

LAVAL, QC / ACCESS Newswire / March 27, 2025 / Bausch Health Companies Inc . (NYSE:BHC) (TSX:BHC) will release first quarter financial results after market close on Wednesday, April 30, 2025. Bausch Health will host a conference call and live webcast at 5:00 p.m. U.S. EDT to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website... Read More

LAVAL, QC / ACCESS Newswire / March 25, 2025 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) (the "Company" or "Bausch Health") today announced that it has priced its previously announced offering (the "Offering") of $4.4 billion aggregate principal amount of 10.000% senior secured notes due 2032 (the "Notes") through its indirect wholly-owned subsidiary, 1261229 B.C. Ltd. (the "Issuer"), a company incorporated under the... Read More

LAVAL, QC / ACCESS Newswire / March 21, 2025 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) (the "Company" or "Bausch Health") today announced that (i) it has delivered conditional notices of redemption for all of its outstanding 5.500% Senior Secured Notes due 2025, 9.000% Senior Notes due 2025, 5.750% Senior Secured Notes due 2027 and 6.125% Senior Secured Notes due 2027 (collectively, the "BHC Notes") and (ii)... Read More

LAVAL, QC / ACCESS Newswire / March 19, 2025 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) (the "Company" or "Bausch Health") today announced that it has launched an offering (the "Offering") of $4.0 billion aggregate principal amount of new senior secured notes due 2032 (the "Notes") through its indirect wholly-owned subsidiary, 1261229 B.C. Ltd., a company incorporated under the laws of British Columbia, Canada (the... Read More

Transaction is part of a broader refinancing initiative aimed at opportunistically accessing capital markets to address near- and mid-term maturities LAVAL, QC / ACCESS Newswire / March 19, 2025 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) (the "Company" or "Bausch Health") today announced that it has launched the syndication of new senior secured credit facilities totaling at least $3.8 billion. The new senior... Read More

LAVAL, QC / ACCESS Newswire / March 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, today provided an update on its financing plans. The Company announced that it has engaged J.P. Morgan in connection with the Company's previously announced financing objectives. Any transactions would be... Read More

Seventh consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP) 1 , delivering results at the high-end and/or exceeding 2024 guidance Fourth Quarter Consolidated Revenues of $2.56 billion, up 6% on a Reported basis and up 9% on an Organic (non-GAAP) 1 basis over the prior year period Full-Year Consolidated Revenues of $9.63 billion, up 10% on a Reported basis and 8% on an Organic... Read More

LAVAL, QC / ACCESS Newswire / February 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC), today announced that it will participate in the 2025 J.P. Morgan Global Leveraged Finance Conference in Miami Beach, Florida on February 24. A live audio webcast of the event will be accessible on the Investor Relations section of Bausch Health's website. Details Date: Monday, February 24, 2025 Time: 8:45 a.m. U.S. EST... Read More

Bausch Health to Provide Scholarships to 10 Students Living with GI Diseases LAVAL, QC / ACCESS Newswire / February 10, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the opening of the 2025 Salix Gastrointestinal Health Scholars Program application period. The program will award 10 exceptional students living with GI disease a... Read More

LAVAL, QC / ACCESS Newswire / February 6, 2025 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following update on a potential sale of its subsidiary, Bausch + Lomb Corporation (NYSE:BLCO)(TSX:BLCO), which was disclosed in December 2024 following a... Read More

LAVAL, QC / ACCESS Newswire / January 23, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release fourth quarter and full year 2024 financial results after market close on Wednesday, February 19, 2025. Bausch Health will host a conference call and live webcast at 5:00 p.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the... Read More

LAVAL, QC / ACCESS Newswire / January 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today acknowledged that the Centers for Medicare and Medicaid Services (CMS) has selected XIFAXAN ® (rifaximin) 550 mg tablets as one of the medicines for the second round of negotiation as part of the Inflation Reduction Act with an initial price applicability in... Read More

LAVAL, QC / ACCESSWIRE / December 12, 2024 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following statement in response to a request from the Canadian Investment Regulatory Organization (CIRO): "As previously disclosed, the Company believes that... Read More

LAVAL, QC / ACCESSWIRE / December 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), alongside the U.S. Pain Foundation (USPF), the International Foundation for Gastrointestinal Disorders (IFFGD), and the American Chronic Pain Association (ACPA) have united to recognize today, Thursday, December 5, as the second annual Opioid-Induced... Read More

LAVAL, QC / ACCESSWIRE / December 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) is pleased to announce the appointment of Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D. This strategic addition to our leadership team underscores our commitment to innovation, excellence, and enriching lives. Jonathan brings a wealth of experience and a proven track record of success... Read More

Next generation product may increase gastrointestinal luminal concentration while limiting system exposure LAVAL, QC / ACCESSWIRE / November 18, 2024 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the first look at its late-stage RED-C clinical trial program which will be presented at the American Association for the Study of Liver... Read More

LAVAL, QC / ACCESSWIRE / November 18, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE/TSX:BHC), today announced that Pr CABTREO TM (clindamycin phosphate, adapalene and benzoyl peroxide) gel 1.2% w/w, 0.15% w/w and 3.1% w/w, a new triple-combination topical prescription treatment for acne vulgaris in patients 12 years of age and older, 1 has received positive reimbursement recommendations from... Read More

Sixth consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP) 1 Third quarter consolidated revenues of $2.51 billion, up 12% on a Reported basis and 9% on an Organic (non-GAAP) 1 basis, with growth in all segments Consolidated GAAP Net Loss Attributable to Bausch Health Companies Inc. of $85 million Consolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP) 1 of... Read More

Additional ACG presentation to focus on impact of Xifaxan on OHE rehospitalizations LAVAL, QC / ACCESSWIRE / October 27, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced that results of an analysis of Xifaxan® (rifaximin) monotherapy will be presented during a Presidential Plenary Session of The American College of Gastroenterology®... Read More

LAVAL, QC / ACCESSWIRE / October 9, 2024 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) will release third quarter 2024 financial results after market close on Wednesday, October 30, 2024. Bausch Health will host a conference call and live webcast at 5:00 p.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website... Read More

Findings show care for chronic liver disease patients is falling on non-specialists who need stronger education and support to ensure patients receive timely, optimal care 1 LAVAL, QC / ACCESSWIRE / October 8, 2024 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today released Liver Health Trends Report in Action , the latest Liver Health Annual... Read More

LAVAL, QC / ACCESSWIRE / September 11, 2024 / Bausch Health , Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the approval by Health Canada of Pr CABTREO TM (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel 1.2%/0.15%/3.1%, a new triple-combination topical prescription treatment for acne vulgaris in patients 12 years of age and older. 1 CABTREO is the first and only... Read More

For Fifth Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 Scholarship LAVAL, QC / ACCESSWIRE / August 13, 2024 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the recipients of its 2024 Salix Gastrointestinal Health Scholars Program. For the fifth year, Bausch Health is proud to award 10... Read More

Second quarter consolidated revenues of $2.40 billion, up 11% on a Reported and 8% on an Organic (non-GAAP) 1 basis Consolidated GAAP Net Income Attributable to Bausch Health Companies Inc. of $10 million Consolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP) 1 of $798 million, up 10% Raising consolidated full-year Revenue and Adjusted EBITDA (non-GAAP) 1 guidance LAVAL, QC / ACCESSWIRE / August... Read More

LAVAL, QC / ACCESSWIRE / July 24, 2024 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) (the "Company") has become aware of a news article issued by Reorg® today, citing unnamed sources. The article contains unsubstantiated rumors, including that the Company is considering a bankruptcy or insolvency proceeding of any kind - it is not. We understand that Reorg® has subsequently issued an update to its original news article... Read More

LAVAL, QC / ACCESSWIRE / July 19, 2024 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) today announced the appointment of two new members to its Executive Leadership Team (ELT). Jean-Jacques Charhon ("JJ") will join the Company as Chief Financial Officer on August 19, 2024. JJ has over 25 years of experience in financial leadership roles with public and private companies across healthcare, high tech and services,... Read More

LAVAL, QC / ACCESSWIRE / July 11, 2024 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) will release second quarter 2024 financial results on Thursday, August 1, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of... Read More

LAVAL, QC / ACCESSWIRE / June 20, 2024 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) ("Bausch Health" or the "Company") and its gastroenterology business, Salix Pharmaceuticals, today announced that it has filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Norwich Pharmaceuticals, Inc. This lawsuit was filed in connection with the Notice of Paragraph IV Certification,... Read More

LAVAL, QC / ACCESSWIRE / June 14, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, recently presented at two global healthcare conferences. Bausch Health's gastroenterology (GI) business, Salix Pharmaceuticals presented data from its Amiselimod clinical trials at Digestive Disease Week (DDW) 2024... Read More

LAVAL, QC / ACCESSWIRE / May 23, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC), today announced additional Canadian public drug plan listings for Pr UCERIS ® (budesonide) aerosol foam to treat mild to moderate distal ulcerative colitis in adults. 1 UCERIS has most recently become available for patients through the public drug plans of Alberta, Prince Edward Island and... Read More

LAVAL, QC / ACCESSWIRE / May 17, 2024 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals , today announced that they will be presenting data from its Phase 2 trial evaluating Amiselimod as treatment for active ulcerative colitis (UC). The data will be presented at Digestive Disease Week (DDW) 2024 during the IMIBD Late Breakers and Innovations in IBD session on... Read More

LAVAL, QC / ACCESSWIRE / May 15, 2024 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) today announced the results of its 2024 annual meeting of shareholders. Annual Meeting Results The 10 directors nominated at the Company's 2024 annual meeting of shareholders held on May 14, 2024, were elected by a vote of the shareholders. The detailed results of the vote for the election of directors are set out below: Name For... Read More

LAVAL, QC / ACCESSWIRE / May 14, 2024 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) and its gastroenterology business Salix Pharmaceuticals, today announced certain updates related to its litigation with Norwich Pharmaceuticals, Inc. With respect to the April 11, 2024, decision of the US Court of Appeals for the Federal Circuit, both Bausch Health and Norwich have filed petitions for panel rehearing or rehearing en... Read More

Xifaxan is the first and only FDA approved medication for the reduction in risk of OHE recurrence in adults Overt Hepatic Encephalopathy is caused by cirrhosis of the liver As complications from chronic liver disease increase, recognizing OHE is critical so that patients can work with their healthcare providers to find the right management plan for them LAVAL, QC / ACCESSWIRE / May 9, 2024 / Bausch Health Companies Inc.... Read More

First quarter revenues of $2.15 billion, up 11% on a Reported and 8% on an Organic 1 basis Year-over-year revenue growth in all segments on both a Reported and Organic 1 Basis GAAP Net Loss Attributable to Bausch Health Companies Inc. of $64 Million Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP) 1 of $665 Million, up 13% Xifaxan ® Appeal Decision Represents a Significant Milestone related to Full... Read More

LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:NHC) (TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the... Read More

LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. Court of Appeals for the Federal Circuit in the matter of Salix Pharmaceuticals, LTD. et al v. Norwich Pharmaceuticals, Inc., affirmed the May 17, 2023 decision of the U.S. District Court for the District of Delaware that had denied Norwich... Read More

LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC), today announced that its topical prescription treatment for acne vulgaris, Pr ARAZLO TM (tazarotene lotion, 0.045% w/w), is now available to patients through BC PharmaCare, the public drug program of British Columbia. ARAZLO is the only tazarotene lotion treatment approved by Health Canada for the... Read More

LAVAL, QC / ACCESSWIRE / April 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) along with its gastroenterology business, Salix Pharmaceuticals, Inc., announced that it filed a lawsuit today in the United States District Court for the District of New Jersey against Amneal Pharmaceuticals of New York, LLC, Amneal EU, Limited, Amneal Pharmaceuticals, LLC, Amneal Pharmaceuticals Private Limited, and Amneal... Read More

LAVAL, QC / ACCESSWIRE / April 3, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC), today announced the first public drug plan listings for Pr UCERIS ® (budesonide) aerosol foam to treat mild to moderate distal ulcerative colitis in adults. 1 UCERIS is now available for patients through the public drug plans of five Canadian provinces: Ontario, Quebec, Saskatchewan, New Brunswick... Read More

Salix Pharmaceuticals Releases Fourth Annual Patient Perspectives IBS Impact Report LAVAL, QC / ACCESSWIRE / April 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today for IBS Awareness Month announced the results from the fourth edition of its annual survey of U.S adults living with irritable bowel syndrome (IBS) or chronic idiopathic... Read More

LAVAL, QC / ACCESSWIRE / March 6, 2024 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced that it is supporting a Phase 2 investigator-initiated study (IIS) of RELISTOR® (methylnaltrexone bromide: MNTX) in patients with resectable head and neck squamous cell carcinoma. An IIS is a study that is proposed, developed, and conducted by a qualified sponsor... Read More

Salix Pharmaceuticals Releases Findings from First Colonoscopy Awareness Survey LAVAL, QC / ACCESSWIRE / March 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced findings from its first colonoscopy awareness and perspective survey conducted in partnership with The Harris Poll. Survey findings come in time for Colorectal Cancer Awareness Month... Read More

LAVAL, QC / ACCESSWIRE / March 1, 2024 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) today announced that members of company management will participate at the Cowen Annual Health Care Conference in Boston on March 5, 2024. The Bausch Health team will be hosting a fireside chat at 12:50 p.m. EST, and a live webcast will be accessible through the Investor Relations section of the Bausch Health website at... Read More

Fourth-Quarter revenues of $2.41 billion, up 10% on a Reported basis and up 4% on an Organic 1 basis Full-Year revenues of $8.76 billion, up 8% on a Reported basis and 7% on an Organic 1 basis Full-Year revenue growth in Salix, International, Solta and Bausch + Lomb segments on both a Reported and Organic 1 basis GAAP Net Loss Attributable to Bausch Health Companies Inc. of $39 million for the quarter and $592 million for... Read More

Salix to Provide Scholarships to 10 Students Living with GI Diseases LAVAL, QC / ACCESSWIRE / February 12, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the opening of the 2024 Salix Gastrointestinal Health Scholars Program application period. The program will award 10 exceptional students living with GI disease a scholarship of up to $10,000 as they work to pursue their higher education goals. "The... Read More

LAVAL, QC / ACCESSWIRE / February 1, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced, as part of its ongoing commitment to board refreshment and board diversity, its nomination of two independent and diverse candidates to stand for election to its Board of Directors at the Company's 2024 Annual Meeting of Shareholders: Christian A. Garcia, Former Executive Vice President and Chief Financial Officer of... Read More

LAVAL, QC / ACCESSWIRE / February 1, 2024 / Bausch Health Companies Inc. (NYSE/TSX:BHC) will release fourth-quarter and full-year 2023 financial results on Thursday, Feb. 22, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the... Read More

LAVAL, QC / ACCESSWIRE / January 30, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced the U.S. launch of CABTREO™ (clindamycin, adapalene, benzoyl peroxide) Topical Gel, 1.2%/0.15%/3.1% indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. "With today's launch of CABTREO, millions of Americans who suffer from acne... Read More

Approval Represents an Important Breakthrough in One of the Largest Medical Aesthetics Markets (*CORRECTION to the release that was posted earlier on January 18, 2024: The TR-4 Return Pad is approved for use by the U.S. Food & Drug Administration (as part of the Thermage FLX device registration) See sentence below.*) LAVAL, QC / ACCESSWIRE / January 18, 2024 / Bausch Health Companies Inc. (NYSE/TSX:BHC) and Solta Medical, a... Read More

Approval Represents an Important Breakthrough in One of the Largest Medical Aesthetics Markets LAVAL, QC / ACCESSWIRE / January 18, 2024 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) and Solta Medical, a global leader in the medical aesthetics market, today announced the approval of Thermage® FLX and the TR-4 Return Pad by China's National Medical Products Administration (NMPA). The TR-4 Return Pad is approved for use... Read More

LAVAL, QC / ACCESSWIRE / January 8, 2024 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that, as scheduled, oral arguments were heard today at the U.S. Court of Appeals for the Federal Circuit (the "Court") in the matter of Salix Pharmaceuticals, LTD et al v. Norwich Pharmaceuticals, Inc. As expected, no ruling was issued by the Court following... Read More

Trial Meets Both Primary and Key Secondary Endpoints LAVAL, QC / ACCESSWIRE / December 21, 2023 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) ("Bausch Health" or the "Company") today announced positive topline results from the Company's Phase 2 study evaluating Amiselimod, an investigative S1P antagonist, for the treatment of ulcerative colitis (UC). "We are thrilled with these impressive topline results, and believe... Read More

LAVAL, QC / ACCESSWIRE / December 18, 2023 / Bausch Health, Canada, part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), ("Bausch Health" or the "Company") today announced that DUOBRII™ (0.01% w/w halobetasol propionate and 0.045% w/w tazarotene), the company's novel topical prescription drug for improving the signs and symptoms of plaque psoriasis in adult patients with moderate to severe disease, 1 is now available to... Read More

BRIDGEWATER, NJ / ACCESSWIRE / December 5, 2023 / Salix Pharmaceuticals, the gastroenterology division of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), The U.S. Pain Foundation (USPF), and The International Foundation for Gastrointestinal Disorders (IFFGD) today announced they are joining forces to declare Tuesday, Dec. 5, Opioid-Induced Constipation (OIC) Awareness Day. OIC Awareness Day aims to bring awareness to an... Read More

This corrects and replaces the release that was disseminated earlier today Lack of OHE-specific diagnostic code in hospitals may increase risk of additional cost, length of hospitalization and additional burdens for patients compared to those with a previous primary OHE diagnosis LAVAL, QC / ACCESSWIRE / November 10, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals,... Read More

Lack of OHE-specific diagnostic code in hospitals may increase risk of additional cost, length of hospitalization and additional burdens for patients compared to those with a previous primary OHE diagnosis LAVAL, QC / ACCESSWIRE / November 10, 2023 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals , today announced findings from a descriptive analysis of a hospital... Read More

Company Introduces Multimedia Resources to Bring Awareness of SAD LAVAL, QC / ACCESSWIRE / November 8, 2023 / As daylight saving time concluded for much of the US on November 5, and as the seasons change and the days grow shorter, many people may find themselves grappling with the onset symptoms of seasonal affective disorder (SAD). SAD is a type of depression that follows a seasonal pattern and most often occurs with the... Read More

Revenue of $2.24 billion, up 9% on both a Reported and Organic 1 basis Year-over-year revenue growth in all segments on both a Reported and Organic Basis GAAP Net Loss Attributable to Bausch Health Companies Inc. of $378 Million Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP) 1 of $830 Million, up 8% Provides updated full-year Revenue and Adjusted EBITDA (non-GAAP) 1 guidance Received U.S. Food and... Read More

LAVAL, QC / ACCESSWIRE / November 1, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, Inc., today announced that the U.S. District Court for the District of Columbia in the matter of Norwich Pharmaceuticals, Inc. v. Becerra, et al. (Case No. 23-cv-01611), denied Norwich Pharmaceuticals, Inc.'s (Norwich) motion in their lawsuit against the U.S. Food and Drug... Read More

First-Ever Television Ad Campaign for APLENZIN ® (bupropion hydrobromide) Airs in October LAVAL, QC / ACCESSWIRE / October 26, 2023 / Bausch Health Companies Inc . (NYSE:BHC)(TSX:BHC) today announced the new release of "Looking Forward," the television ad campaign for APLENZIN ® (bupropion hydrobromide) extended-release tablets for individuals diagnosed with seasonal affective disorder (SAD), a type of depression that... Read More

First and only FDA-approved fixed-dose, triple-combination topical treatment LAVAL, QC / ACCESSWIRE / October 20, 2023 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for CABTREO TM (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel... Read More

Hurdles Led to Almost All Patients Having At Least One Day Delay to Receive Treatment with Xifaxan® LAVAL, QC / ACCESSWIRE / October 17, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced findings from a retrospective database analysis of adjudicated claims data that examined the impact of access barriers for commercially-insured adults prescribed... Read More

LAVAL, QC / ACCESSWIRE / October 12, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release its third-quarter financial results on Thursday, Nov. 2, 2023. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EDT to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of... Read More

Salix Pharmaceuticals' Liver Health Annual Trends Report Findings Suggest Chronic Liver Disease (CLD) Deaths Could Triple Before the End of the Decade Based Primarily on HCP-Market Research, Report Finds a Growing Concern of Staffing Shortages Across Multiple Healthcare Professions that Treat Liver Disease LAVAL, QC / ACCESSWIRE / October 10, 2023 / Salix Pharmaceuticals , the gastroenterology business of Bausch Health... Read More

Bellamy Young is Moving Past Stigma as She Speaks Candidly about Her Father's Struggle with Chronic Liver Disease/Cirrhosis and Resulting Hepatic Encephalopathy 80% of people with chronic liver disease develop some form of HE 9 in 10 HE patient caregivers report "they did not realize what they were in for at the time of diagnosis" UnderstandingHE.com provides educational tools and resources to support patients and caregivers... Read More

LAVAL, QC / ACCESSWIRE / September 29, 2023 / Bausch + Lomb Corporation ("Bausch + Lomb") (NYSE/TSX:BLCO), a subsidiary of Bausch Health Companies Inc. (the "Company" or "Bausch Health") (NYSE/TSX:BHC), today announced it has completed its acquisition of XIIDRA ® (lifitegrast ophthalmic solution) 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation... Read More

Partnership Aims to Educate Hispanic Communities About the Signs, Symptoms, and Prevalence of Gum Disease Collaboration Launches During Hispanic Heritage Month With Activations Featuring Patient Ambassador Alex Rodriguez LAVAL, QC / ACCESSWIRE / September 21, 2023 / In honor of Hispanic Heritage Month, Bausch Health Companies Inc. (NYSE:BHC),(TSX:BHC) and its oral health care business, OraPharma , today announced its... Read More

LAVAL, QC / ACCESSWIRE / September 18, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC) ("BHC" or the "Company") today announced that Tom Vadaketh, Executive Vice President, Chief Financial Officer, has resigned from his role to pursue another opportunity, and will be leaving the Company effective October 13, 2023. The Company thanks Mr. Vadaketh for his significant contributions and leadership during a period of... Read More

LAVAL, QE / ACCESSWIRE / September 12, 2023 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) is pleased to announce that following its approval by Health Canada the new treatment Pr UCERIS ® (budesonide) aerosol foam is now available across Canada to treat mild to moderate distal ulcerative colitis in adults. UCERIS is the only glucocorticosteroid rectal foam available in Canada indicated for the induction of remission in... Read More

LAVAL, QC / ACCESSWIRE / September 6, 2023 / Bausch + Lomb Corporation (NYSE/TSX:BLCO), a subsidiary of Bausch Health Companies Inc. (NYSE/TSX:BHC), announced that it has disclosed certain historical and pro forma financial information with respect to its previously announced proposed acquisition of XIIDRA® (lifitegrast ophthalmic solution) 5% and certain other ophthalmology assets (the "Acquisition") on a Current Report on... Read More

Favorable Motion Ruling in Xifaxan® Litigation Reinforces Continuing Salix Growth Strategy Balance Sheet Initiatives Further Enhance Liquidity Profile Continued Evaluation of Optimal Implementation of Potential Bausch + Lomb Distribution Revenue of $2.17 billion, Up 10% Reported and 11% Organic 1 GAAP Net Income Attributable to Bausch Health Companies Inc. of $26 Million Adjusted EBITDA Attributable to Bausch Health... Read More

Scholarships Awarded to Six Students Affected by Dermatologic Conditions LAVAL, QC / ACCESSWIRE / July 27, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced the recipients of their 2023 Aspire Higher Scholarship program. The program, which has provided a total of $978,000 in scholarships since launching in 2013, will award six students who have been... Read More

LAVAL, QC / ACCESSWIRE / July 13, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC) will release its second-quarter financial results on Thursday, Aug. 3, 2023. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EDT to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.... Read More

For Fourth Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 Scholarship LAVAL, QC / ACCESSWIRE / July 11, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced the winners of its 2023 Salix Gastrointestinal Health Scholars Program. For the fourth consecutive year, Salix will be awarding $10,000 each to 10 students... Read More

Oral Health Care Companies Celebrate the 100 th ADHA Conference by Highlighting New Data for the Treatment of Periodontal Disease LAVAL, QC / ACCESSWIRE / July 7, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC) and its oral health care business, OraPharma, today announced its presence at the American Dental Hygienists' Association (ADHA®) Annual Conference held in Chicago, IL from July 7-9, 2023. ADHA is the largest and... Read More

LAVAL, QC / ACCESSWIRE / July 7, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC) and KKR today announced that Bausch Receivables Funding LP, an Ontario limited partnership and wholly-owned subsidiary of Bausch Health, has entered into a $600 million non-recourse financing facility with KKR and its credit funds and accounts. The facility will be collateralized by certain accounts receivables originated by a wholly-owned... Read More

LAVAL, QC / ACCESSWIRE / June 30, 2023 / Bausch + Lomb Corporation (NYSE/TSX:BLCO), a subsidiary of Bausch Health Companies Inc. (NYSE/TSX:BHC), announced that it has entered into a definitive agreement with Novartis to acquire XIIDRA® (lifitegrast ophthalmic solution) 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease (DED) focusing on inflammation associated with dry eye.... Read More

Three XIFAXAN® (rifaximin) Research Posters to Be Featured LAVAL, QC / ACCESSWIRE / June 19, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced its presence at the European Association for the Study of the Liver ( EASL ) Congress 2023. XIFAXAN® (rifaximin) data was selected for inclusion in the Cirrhosis and its complication's session. EASL... Read More

LAVAL, QC / ACCESSWIRE / June 6, 2023 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, understand that in a June 2, 2023, letter, the U.S. Food and Drug Administration (FDA) granted Norwich Pharmaceuticals Inc. Tentative Approval of its Abbreviated New Drug Application (ANDA) for XIFAXAN® (rifaximin) 550 mg. At the same time, the FDA confirmed in its Letter that it... Read More

Cover Your Bases Campaign Kicks Off Oral Health Month with ARESTIN (minocycline HCI) Patient Ambassador Alex Rodriguez LAVAL, QC , May 31, 2023 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its oral health care business, OraPharma, today announced its collaboration with World Series Champion, Alex Rodriguez , to launch a national awareness campaign about the prevalence and impact of gum disease. The Cover... Read More

Novel Trial to Study the Reduction of Certain Pathogens Following Scaling and Root Planing Procedure LAVAL, QC / ACCESSWIRE / May 18, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its oral health care business, OraPharma, today announced the publication of a new study, which showed that ARESTIN ® (minocycline HCI) microspheres, 1mg decreased certain pathogenic burdens, also known as infection burdens, in adults... Read More

LAVAL, QC / ACCESSWIRE / May 17, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. District Court of Delaware in the matter of Salix Pharmaceuticals, LTD et al v. Norwich Pharmaceuticals, Inc., has denied Norwich Pharmaceuticals' motion to modify the Court's final judgment that prevents the U.S. Food and Drug Administration (FDA) from... Read More

LAVAL, QC / ACCESSWIRE / May 17, 2023 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) today announced the results of its 2023 annual meeting of shareholders (the "Annual Meeting"). The 10 directors nominated at the Company's Annual Meeting held on May 16, 2023, were elected by a vote of the Company's shareholders. The detailed results of the vote for the election of directors are set out below: Name For Withheld Broker... Read More

LAVAL, QC / ACCESSWIRE / May 10, 2023 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) is proud to recognize May as Mental Health Awareness Month by continuing efforts that highlight the importance of educating and supporting those with mental health care needs. With more people finding value in speaking with a mental health professional and seeking treatment, this heightened focus on mental health has never been more... Read More

Five XIFAXAN® (rifaximin) and TRULANCE® (plecanatide) Research Posters Also to Be Presented LAVAL, QC / ACCESSWIRE / May 8, 2023 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), the gastroenterology (GI) business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and one of the largest specialty pharmaceutical companies in the world... Read More

First-Quarter revenues of $1.94 billion, up 1% reported and 4% organic 1 Solid revenue growth across core products, led by Xifaxan with 7% reported growth Mid- and late-stage product pipeline advancing Bausch Health provides consolidated full-year guidance, and Bausch Health (excl. B+L) confirms 2023 guidance LAVAL, QC / ACCESSWIRE / May 4, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the... Read More

New treatment from Bausch Health, Canada indicated to treat seasonal allergy and associated ocular symptoms in adults, adolescents and children 6 years and older LAVAL, QC , May 3, 2023 /CNW/ - Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) is pleased to announce the availability across Canada of its new prescription treatment RYALTRIS ® (olopatadine hydrochloride and mometasone furoate nasal spray). RYALTRIS has been... Read More

PDUFA Action Date is October 20, 2023 LAVAL, QC / ACCESSWIRE / May 1, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational IDP-126 (clindamycin 1.2%/adapalene 0.15%/benzoyl peroxide 3.1%) Gel with a Prescription Drug User Fee Act (PDUFA) action... Read More

Program Seeks to Increase the Number of People Screened to Help Prevent Colorectal Cancer Diagnoses in Philadelphia LAVAL, QC / ACCESSWIRE / April 24, 2023 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced a partnership with the Colorectal Cancer Alliance (Alliance), the nation's nonprofit leader dedicated to combatting colorectal cancer, to increase... Read More

LAVAL, QC / ACCESSWIRE / April 13, 2023 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) will release its first-quarter financial results on Thursday, May 4, 2023. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EDT to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the... Read More

Salix Pharmaceuticals Releases Third Annual Patient Perspectives Report LAVAL, QC / ACCESSWIRE / April 4, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today announced the results from the third edition of its patient perspectives survey, an annual survey of U.S. adults living with irritable bowel syndrome (IBS) or chronic idiopathic constipation (CIC).... Read More

LAVAL, QC / ACCESSWIRE / March 1, 2023 / Bausch Health Companies Inc. (TSX:BHC) (NYSE:BHC) today announced that Richard De Schutter and Dr. Argeris Karabelas are retiring from the Company's Board of Directors, effective as of the upcoming 2023 annual meeting of shareholders of the Company. Following the retirements of Mr. De Schutter and Dr. Karabelas, the size of the Board will be reduced to 10 directors. "Dick and Jerry... Read More

Fourth-Quarter revenues of $2.2 billion, flat reported, up 4% organic 1 Full-Year revenues of $8.1 billion, down 4% reported, up 2% organic 1 Unrestricted B+L from BHC covenants Reduced debt by $464 million in the fourth quarter Provides 2023 guidance for Bausch Health (excl. B+L) LAVAL, QC / ACCESSWIRE / February 23, 2023 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) today announced its fourth-quarter and full-year... Read More

Salix to Provide Scholarships to 10 Students Living with GI Diseases LAVAL, QC / ACCESSWIRE / February 13, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC) today announced the opening of the 2023 Salix Gastrointestinal Health Scholars Program application period. The program will award 10 exceptional students living with GI disease a scholarship of up to $10,000 as they work to pursue their higher education goals. "At... Read More

LAVAL, QC / ACCESSWIRE / February 1, 2023 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) will release its fourth-quarter and full-year financial results on Thursday, Feb. 23, 2022. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior... Read More

LAVAL, QC , Dec. 22, 2022 /CNW Telbec/ - Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) and its Canadian dermatology division, one of the largest prescription dermatology health care businesses in Canada, today announced that its new topical prescription treatment for acne vulgaris, ARAZLO TM (tazarotene lotion, 0.045% w/w), is now available to patients through the provincial public drug plans of Quebec , Ontario ,... Read More

LAVAL, QB / ACCESSWIRE / December 2, 2022 / Bausch Health Companies Inc. (NYSE/TSX:BHC) today announced that the US District Court for the District of New Jersey issued a favorable decision regarding DUOBRII® and BRYHALI®, in a suit filed against Padagis Israel Pharmaceuticals LTD and Padagis US LLC. According to the ruling, the District Court found all the asserted patents valid and infringed. The current decision will... Read More

Launching in December for Constipation Awareness Month, Initiatives Include Partnerships with Well-Known Lifestyle and Health Care Practitioner Influencers Campaign Coincides with Salix's Continued Support of Advocacy Groups Building Innovative Patient Education Programs and Advancing Disease State Research in 2023 LAVAL, QC / ACCESSWIRE / December 1, 2022 / Salix Pharmaceuticals ("Salix"), the gastroenterology business of... Read More

LAVAL, QC / ACCESSWIRE / November 29, 2022 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) ("Bausch Health" or the "Company") has designated 1261229 B.C. Ltd., the entity that directly or indirectly holds 88.7% of the issued and outstanding shares of Bausch + Lomb Corporation ("Bausch + Lomb"), as an unrestricted subsidiary of the Company in accordance with the terms of the Company's debt documents. In connection... Read More